Document Detail

A new era in noninvasive prenatal testing.
MedLine Citation:
PMID:  24283242     Owner:  NLM     Status:  In-Data-Review    
To the Editor: In their Perspective article, Morain et al. (Aug. 8 issue)(1) say that commercial companies have not met reasonable standards for demonstrating clinical validity. This is not correct. In five independent cohorts, researchers have examined 463 pregnancies with fetuses with Down's syndrome, 187 with trisomy 18, and 37 with trisomy 13. To maximize confidence in sensitivity estimates, all were high-risk pregnancies (in a general population, more than 250,000 pregnancies would have had to be studied). Five professional organizations, including the American Congress of Obstetricians and Gynecologists,(2) recommend offering such testing for "high-risk" pregnancies. The Perspective article also implies . . .
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  369     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2164-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Engineered in India - patent law 2.0.
Next Document:  A new era in noninvasive prenatal testing.